Leadership Changes at Coloplast Drive Strategic Growth Forward
Coloplast Restructures Leadership to Embrace New Strategy
Coloplast is excited to share significant changes to its Executive Leadership Team (ELT), a move aimed at better supporting the latest strategic goals of the Coloplast Group.
Shaping a Customer-Centric Strategy
The past few months have seen dedicated collaboration from senior leaders across the Coloplast organization, culminating in a new strategy designed to prioritize customer needs. This customer-first approach will guide how Coloplast interacts with its users, patients, and clinicians by enhancing the overall experience.
Interim CEO Lars Rasmussen expresses the company's commitment: "Our new strategy puts customers at the forefront of everything we do. We aspire to lead the market and set new standards in healthcare provision!"
To truly innovate and provide exceptional value, Coloplast recognizes the necessity of transforming its operational framework and enhancing its product development timelines.
With the recent acquisitions of Atos Medical and Kerecis, Coloplast is restructuring its operations into two defined units: Chronic Care and Acute Care. This approach acknowledges the unique market conditions and patient pathways associated with different healthcare sectors.
Revolutionizing Chronic Care
Effective immediately, a distinct Chronic Care Commercial business unit will be established, consolidating existing sales regions and critical commercial roles. This unit will also integrate Atos Medical’s Voice & Respiratory Care segment due to its alignment with chronic patient needs.
To enhance innovation and expedite product deliveries, Coloplast will concurrently establish an independent R&D department specifically for Chronic Care.
“Given the substantial restructuring in Chronic Care, we have mutually agreed for Nicolai Buhl, Executive Vice President, to depart from Coloplast. Nicolai has made significant contributions, especially in Wound Care and Chronic Care,” notes Lars, acknowledging Nicolai's leadership.
Caroline Vagner Rosenstand will assume the role of Executive Vice President, leading the new Chronic Care Commercial unit. Her proven track record in executing commercial strategies positions her well for success in this role.
Also, set to take charge of Chronic Care R&D starting November 1st is Rasmus Just. Rasmus brings with him invaluable experience from his earlier roles at Coloplast and recent tenure at Novo Nordisk.
“We are excited to welcome Rasmus back as he brings a robust focus on technology and business, crucial for our growth,” says Lars.
Introducing the Acute Care Unit
The newly formed Acute Care section encompasses Interventional Urology, Advanced Wound Dressings, and Kerecis. Noteworthy products include Coloplast's innovative penile implants and advanced wound care solutions, which are primarily utilized in specialized medical environments.
Immediate changes include merging the Advanced Wound Dressings with Kerecis into a unified Wound & Tissue Repair organization, directed by Executive Vice President Fertram Sigurjonsson. This merger aims to amplify innovation and improve global presence.
“Fertram's capabilities in innovation have already set a strong foundation for Kerecis. This integration is a crucial step towards enhancing our combined market offerings,” shares Lars.
Importantly, the Interventional Urology operations will remain unchanged under the leadership of Executive Vice President Tommy Johns.
“Congratulations to Caroline, Fertram, and Rasmus as they take on these pivotal roles,” concludes Lars.
Meet the New Executive Leadership Team
- Lars Rasmussen, interim CEO
- Anders Lonning-Skovgaard, EVP & CFO
- Allan Rasmussen, EVP Global Operations
- Dorthe Rønnau, EVP People & Culture
- Caroline Vagner Rosenstand, EVP Chronic Care Commercial
- Rasmus Just, EVP Chronic Care R&D (commencing 1 November)
- Fertram Sigurjonsson, EVP Wound & Tissue Repair
- Tommy Johns, EVP Interventional Urology
Management registered with the Danish Business Authority is composed of Lars Rasmussen and Anders Lonning-Skovgaard.
Contact Information
Peter Mønster
Sr. Media Relations Manager
Tel. +45 4911 2623
Email: dkpete@coloplast.com
Aleksandra Dimovska
Vice President, Investor Relations
Tel. +45 4911 2458
Email: dkadim@coloplast.com
Kristine Husted Munk
Senior Manager, Investor Relations
Tel. +45 4911 3266
Email: dkkhu@coloplast.com
Simone Dyrby Helvind
Senior Manager, Investor Relations
Tel. +45 4911 2981
Email: dksdk@coloplast.com
Coloplast continues to provide innovative healthcare solutions worldwide, responding to the needs of those who depend on quality intimate healthcare. Our journey began with a nurse's vision and has grown to serve millions globally.
Frequently Asked Questions
What are the primary goals of Coloplast's new strategy?
The new strategy aims to enhance customer experience, innovate products faster, and ensure the company leads in the healthcare market.
Who is the interim CEO of Coloplast?
Lars Rasmussen is currently serving as the interim CEO.
What new units has Coloplast established?
Coloplast has created two units: Chronic Care and Acute Care, to focus on respective market needs and dynamics.
When will Rasmus Just begin his new role?
Rasmus Just will begin his role as EVP of Chronic Care R&D on November 1st.
What products are included in the Acute Care unit?
Products in the Acute Care unit include Coloplast's penile implants, Advanced Wound Dressings, and Kerecis's fish skin portfolio.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.